AGO Research GmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1993-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ago-ovar.de
Clinical Trials
30
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
- Conditions
- Recurrent Vulvar CancerPersistent Vulvar CancerMetastatic Vulva CancerLocally Advanced Vulvar Cancer
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 42
- Registration Number
- NCT05903833
- Locations
- 🇩🇪
Universitätsklinikum Augsburg, Augsburg, Germany
🇩🇪Hochtaunus-Kliniken Bad Homburg, Bad Homburg, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
- Conditions
- Primary Peritoneal CancerRecurrent Ovarian CancerRecurrent Fallopian Tube Cancer
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT05126342
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT04644289
- Locations
- 🇩🇪
Universitätsklinikum Mannheim GmbH, Frauenklinik, Mannheim, Baden-Württemberg, Germany
🇩🇪Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Frauenheilkunde, München, Bayern, Germany
🇩🇪KEM Essen | Evang. Kliniken Essen Mitte, Essen, North Rine-Westphalia, Germany
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
- Conditions
- Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 136
- Registration Number
- NCT04274426
- Locations
- 🇩🇪
Charite Campus Virchow Klinikum, Berlin, Germany
🇩🇪Städtische Klinikum Dessau, Dessau, Germany
🇩🇪Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden, Dresden, Germany
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
- Conditions
- Recurrent Ovarian Carcinoma
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 9
- Registration Number
- NCT03690739
- Locations
- 🇩🇪
Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Bayern, Germany
🇩🇪Hochtaunus-Kliniken, Bad Homburg, Germany
🇩🇪Sozialstiftung Bamberg, Bamberg, Germany
- Prev
- 1
- 2
- Next